DBV Technologies S.A. DBVT
At closeNov 4, 2026, 4:00 PM EST
After hours · Nov 4, 4:00 PM ET
- YTD
- -48.15%
- 1 year
- -30.78%
- Market cap
- 624.64M
- Revenue (ttm)
- 5.74M
- EPS (ttm)
- -2.93
- Shares out
- 59.19M
- Forward P/E
- -35.12
- YTD return
- -48.15%
- 1-year return
- -30.78%
- Volume
- 378.31K
- Avg volume
- 368.08K
- Open
- 10.04
- Previous close
- 10.11
- Day's range
- 9.76 – 10.41
- 52-week range
- 8.63 – 26.19
- Beta
- -0.21
- Analysts
- Buy
- Price target
- 40.71 (+309.5%)
- Earnings date
- Oct 28, 2026
2Y +9.35 (+1228.52%)
Key statistics
- Enterprise value
- 700.74M
- PEG ratio
- 0.00
- Price / sales
- 179.03
- Price / book
- 4.94
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 12.50%
- Free cash flow
- -87.21M
- Total cash
- 229.20M
- Total debt
- 6.10M
- Return on equity
- -158.89%
- Short % of float
- 2.41%
- 50-day average
- 18.07
- 200-day average
- 17.93
Analyst view
Consensus: buy
- Target (low)
- 5.82
- Target (mean)
- 40.71
- Target (high)
- 54.99
- Strong buy1
- Buy4
- Hold0
- Sell1
- Strong sell0
Next earnings
Oct 28, 2026
Expected Oct 28, 2026. Consensus EPS estimate -0.09367.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 28, 2026 | Sep 30, 2026 | -0.16141 | — | — | — |
| Jul 16, 2026 | Jun 30, 2026 | -0.12 | -0.1373 | -0.02 | -14.42% |
| Apr 30, 2026 | Mar 31, 2026 | -0.14 | -0.56 | -0.42 | -300.00% |
| Mar 27, 2026 | Dec 31, 2025 | -1.30 | -1.15 | +0.15 | +11.54% |
| Oct 28, 2025 | Sep 30, 2025 | -1.45 | -1.20 | +0.25 | +17.24% |
| Jul 29, 2025 | Jun 30, 2025 | -0.21 | -1.55 | -1.34 | -638.10% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 30, 2026 | Citizens | main | Market Outperform | Market Outperform |
| May 4, 2026 | Guggenheim | reit | Buy | Buy |
| May 1, 2026 | Citizens | main | Market Outperform | Market Outperform |
| Mar 27, 2026 | Citizens | main | Market Outperform | Market Outperform |
| Mar 27, 2026 | Guggenheim | reit | Buy | Buy |
| Dec 17, 2025 | HC Wainwright & Co. | main | Buy | Buy |
About DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- France
- Website
- dbv-technologies.com
News
DBV Technologies to Participate in Upcoming November Investor Conferences 
Guggenheim Maintains Buy on DBV Technologies, Lowers Price Target to $46 
Citizens Maintains Market Outperform on DBV Technologies, Lowers Price Target to $47 
12 Health Care Stocks Moving In Thursday's Pre-Market Session 
ServiceNow Posts Downbeat Q3 Earnings, Joins Sprouts Farmers Market, Alphabet And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session 
DBV Technologies S.A. (DBVT) Q3 2026 Earnings Call Transcript 
What DBV Technologies (DBVT) Said on Its Q3 Earnings Call 
DBV Technologies Q3 2026 Earnings Call Transcript 
DBV Technologies Q3 EPS $(0.14) Beats $(0.24) Estimate, Sales $1.600M Beat $820.000K Estimate 
DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update
Your note
Sign in to keep a note on DBVT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| MOHIDEEN PHARIS | Officer | Sale | Jan 28, 2026 | 144,995 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| MPM Bioimpact LLC | 8.80% | 5,213,361 | 90.45M | Mar 30, 2026 |
| Vivo Capital, LLC | 4.51% | 2,667,569 | 46.28M | Mar 30, 2026 |
| Artisan Partners Limited Partnership | 3.75% | 2,219,386 | 38.51M | Mar 30, 2026 |
| Siren, L.L.C. | 3.14% | 1,857,362 | 32.23M | Mar 30, 2026 |
| Baker Bros. Advisors, LP | 2.47% | 1,461,425 | 25.36M | Mar 30, 2026 |
| Adar1 Capital Management, LLC | 1.71% | 1,012,866 | 17.57M | Mar 30, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Artisan Partners Funds Inc.-Artisan International Small-Mid Fund | 2.30% | 1,363,189 | 23.65M | Mar 30, 2026 |
| RUSSELL INVESTMENT CO-Tax-Managed U.S. Mid & Small Cap Fund | 0.08% | 45,089 | 782.29K | Apr 29, 2026 |
| AdvisorShares Trust-AdvisorShares Dorsey Wright ADR ETF | 0.07% | 44,095 | 765.05K | May 30, 2026 |
| RUSSELL INVESTMENT CO-U.S. Small Cap Equity Fund | 0.04% | 22,707 | 393.97K | Apr 29, 2026 |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 0.02% | 8,897 | 154.36K | May 30, 2026 |
| RUSSELL INVESTMENT FUNDS-U.S. Small Cap Equity Fund | 0.01% | 5,834 | 101.22K | Mar 30, 2026 |